Use: Labeled indications
- Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD)
- .
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ACIPHEX delayed-release tablets is a proton pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) (1.1). Maintenance of Healing of Erosive or Ulcerative GERD (1.2). Treatment of Symptomatic GERD (1.3). Healing of Duodenal Ulcers (1.4).
Helicobacter pylori Eradication to Reduce Risk of Duodenal Ulcer Recurrence (1.5). Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome (1.6). In adolescent patients 12 years of age and older for: Short-term Treatment of Symptomatic GERD (1.7). 1.1 Healing of Erosive or Ulcerative GERD in Adults ACIPHEX delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD).
For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered. 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults ACIPHEX delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. 1.3 Treatment of Symptomatic GERD in Adults ACIPHEX delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults for up to 4 weeks. 1.4 Healing of Duodenal Ulcers in Adults ACIPHEX delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers.
Most patients heal within four weeks. 1.5 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults ACIPHEX delayed-release tablets, in combination with amoxicillin and clarithromycin as a three drug regimen, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.2) and the full prescribing information for clarithromycin]. 1.6 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults ACIPHEX delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. 1.7 Treatment of Symptomatic GERD in Adolescent Patients 12 Years of Age and Older ACIPHEX delayed-release tablets are indicated for the treatment of symptomatic GERD in adolescents 12 years of age and above for up to 8 weeks.
Contraindications
4 CONTRAINDICATIONS ACIPHEX is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles, or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.3), Adverse Reactions (6)].
PPIs, including ACIPHEX, are contraindicated with rilpivirine-containing products [see Drug Interactions (7)]. For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with ACIPHEX delayed-release tablets, refer to the Contraindications section of their package inserts.
Patients with a history of hypersensitivity to rabeprazole (4). PPIs, including ACIPHEX delayed-release tablets, are contraindicated in patients receiving rilpivirine-containing products (4, 7). Refer to the Contraindications section of the prescribing information for clarithromycin and amoxicillin, when administered in combination with ACIPHEX (4).
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2 DOSAGE AND ADMINISTRATION Table 1 shows the recommended dosage of ACIPHEX delayed-release tablets in adults and adolescent patients 12 years of age and older. The use of ACIPHEX delayed-release tablets is not recommended for use in pediatric patients 1 year to less than 12 years of age because the lowest available tablet strength (20 mg) exceeds the recommended dose for these patients.
Use another rabeprazole formulation for pediatric patients 1 year to less than 12 years of age. Table 1: Recommended Dosage and Duration of ACIPHEX Delayed-Release Tablets in Adults and Adolescents 12 Years of Age and Older Indication Dosage of ACIPHEX delayed-release tablets Treatment Duration Adults Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) 20 mg once daily 4 to 8 weeks For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of ACIPHEX may be considered.
Maintenance of Healing of Erosive or Ulcerative GERD 20 mg once daily Controlled studies do not extend beyond 12 months Symptomatic GERD in Adults 20 mg once daily Up to 4 weeks If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered. Healing of Duodenal Ulcers 20 mg once daily after the morning meal Up to 4 weeks Most patients heal within 4 weeks; some patients may require additional therapy to achieve healing.
Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence ACIPHEX 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg Take all three medications twice daily with morning and evening meals; it is important that patients comply with the full 7-day regimen [see Clinical Studies (14.5)] 7 days Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome Starting dose 60 mg once daily then adjust to patient needs; some patients require divided doses Dosages of 100 mg once daily and 60 mg twice daily have been administered As long as clinically indicated Some patients with Zollinger-Ellison syndrome have been treated continuously for up to one year Adolescents 12 Years of Age and Older Symptomatic GERD 20 mg once daily Up to 8 weeks Administration Instructions Swallow ACIPHEX delayed-release tablets whole. Do not chew, crush, or split tablets.
For the treatment of duodenal ulcers take ACIPHEX delayed-release tablets after a meal. For Helicobacter pylori eradication take ACIPHEX delayed-release tablets with food. For all other indications ACIPHEX delayed-release tablets can be taken with or without food. Take a missed dose as soon as possible. If it is almost time for the next dose, skip the missed dose and go back to the normal schedule.
Do not take two doses at the same time. Indication Recommended Dosage (2) Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) 20 mg once daily for 4 to 8 weeks Maintenance of Healing of Erosive or Ulcerative GERD* studied for 12 months 20 mg once daily* Symptomatic GERD in Adults 20 mg once daily for 4 weeks Healing of Duodenal Ulcers 20 mg once daily after morning meal for up to 4 weeks Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Three Drug Regimen: ACIPHEX 20 mg Amoxicillin 1000 mg Clarithromycin 500 mg All three medications should be taken twice daily with morning and evening meals for 7 days Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome Starting dose 60 mg once daily then adjust to patient needs Symptomatic GERD in Adolescents 12 Years of Age and Older 20 mg once daily for up to 8 weeks Administration Instructions (2): Swallow ACIPHEX delayed-release tablets whole.
Do not chew, crush or split the tablets. For the treatment of duodenal ulcers take ACIPHEX delayed-release tablets after a meal. For Helicobacter pylori eradication take ACIPHEX delayed-release tablets with food. For all other indications ACIPHEX delayed-release tablets can be taken with or without food.
Dosing: Altered kidney function
Patients with Renal Impairment: In 10 patients with stable end-stage renal disease requiring maintenance hemodialysis (creatinine clearance ≤5 mL/min/1.73 m²), no clinically significant differences were observed in the pharmacokinetics of rabeprazole after a single 20 mg dose of ACIPHEX delayed-release tablets when compared to 10 healthy subjects.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment Administration of ACIPHEX delayed-release tablets to patients with mild to moderate hepatic impairment (Child-Pugh Class A and B, respectively) resulted in increased exposure and decreased elimination [see Clinical Pharmacology (12.3)]. No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.
There is no information in patients with severe hepatic impairment (Child-Pugh Class C). Avoid use of ACIPHEX delayed-release tablets in patients with severe hepatic impairment; however, if treatment is necessary, monitor patients for adverse reactions [see Warnings and Precautions (5), Adverse Reactions (6)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of ACIPHEX delayed-release tablets have been established in pediatric patients for adolescent patients 12 years of age and older for the treatment of symptomatic GERD. Use of ACIPHEX delayed-release tablets in this age group is supported by adequate and well controlled studies in adults and a multicenter, randomized, open-label, parallel-group study in 111 adolescent patients 12 to 16 years of age.
Patients had a clinical diagnosis of symptomatic GERD, or suspected or endoscopically proven GERD and were randomized to either 10 mg or 20 mg once daily for up to 8 weeks for the evaluation of safety and efficacy. The adverse reaction profile in adolescent patients was similar to that of adults. The related reported adverse reactions that occurred in ≥2% of patients were headache (5%) and nausea (2%).
There were no adverse reactions reported in these studies that were not previously observed in adults. The safety and effectiveness of ACIPHEX delayed-release tablets have not been established in pediatric patients for: Healing of Erosive or Ulcerative GERD Maintenance of Healing of Erosive or Ulcerative GERD Treatment of Symptomatic GERD Healing of Duodenal Ulcers Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ACIPHEX delayed-release 20 mg tablets are not recommended for use in pediatric patients less than 12 years of age because the tablet strength exceeds the recommended dose for these patients [see Dosage and Administration (2)].
For pediatric patients 1 year to less than 12 years of age consider another rabeprazole formulation. The safety and effectiveness of a different dosage form and dosage strength of rabeprazole has been established in pediatric patients 1 to 11 years for the treatment of GERD. Juvenile Animal Data Studies in juvenile and young adult rats and dogs were performed.
In juvenile animal studies rabeprazole sodium was administered orally to rats for up to 5 weeks and to dogs for up to 13 weeks, each commencing on Day 7 post-partum and followed by a 13-week recovery period. Rats were dosed at 5, 25, or 150 mg/kg/day and dogs were dosed at 3, 10, or 30 mg/kg/day. The data from these studies were comparable to those reported for young adult animals.
Pharmacologically mediated changes, including increased serum gastrin levels and stomach changes, were observed at all dose levels in both rats and dogs. These observations were reversible over the 13-week recovery periods. Although body weights and/or crown-rump lengths were minimally decreased during dosing, no effects on the development parameters were noted in either juvenile rats or dogs.
When juvenile animals were treated for 28 days with a different PPI at doses equal to or greater than 34 times the daily oral human dose on a body surface area basis, overall growth was affected and treatment-related decreases in body weight (approximately 14%) and body weight gain, and decreases in femur weight and femur length were observed.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the total number of subjects (n=2009) in clinical studies of ACIPHEX delayed-release tablets, 19% were 65 years and over, while 4% were 75 years and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Dosage forms
Philippines
- Enteric-coated tablet: 10 mg, 20 mg
- Lyophilized powder for injection: 20 mg
- Powder for injection: 20 mg
- Powder for solution for intravenous injection: 20 mg
- Lyophilized powder for intravenous injection: 20 mg
- Powder for intravenous injection: 20 mg
- Tablet: 10 mg, 20 mg
- Capsule: 20 mg
- Delayed-release tablet: 20 mg
- Powder for solution for injection: 20 mg
and 1 more forms; see the products table.
Registered products in the Philippines
51 products registered with the Food and Drug Administration (FDA) Philippines list Rabeprazole as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products51
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AzloRabeprazole Sodium | 20mg Enteric Coated TabletAlu/Alu Blister Pack X 10'S (Box of 30's) | Rx | Lincoln Pharmaceuticals Ltd.India | Despina Pharma, Inc. | DRP-11672 | Apr 11, 2027 | |
BaroleRabeprazole Sodium | 20 mg Lyophilized Powder For Injection (IV)USP Type I Clear Glass Vial with red flip-off seal x 10mL (Box of 1's) | Rx | GUFIC BIOSCIENCES LIMITEDIndia | METRO DRUG, INC.Importer: MEGA LIFESCIENCES LIMITED INC.Trader: MEGA LIFESCIENCES (AUSTRALIA) PTY. LTD. | DR-XY43184 | Feb 10, 2029 | |
Barole 20Rabeprazole Sodium | 20 mg CapsuleStrip Foil x 10's (Box of 30's) | Rx | Inventia Healthcare LimitedIndia | Metro Drug Inc.Importer: Mega Lifesciences Limited IncTrader: Mega Lifesciences (Australia) Pty. Ltd. | DR-XY37066 | Aug 23, 2027 | |
BenzablocRabeprazole sodium | 20 mg Enteric-Coated TabletAlu/Alu Blister pack x 10's (Box of 30's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Largen Med Inc.Importer: Aglobal Care, Inc. | DRP-13842-02 | Apr 28, 2028 | |
CentrabezRabeprazole Sodium | 20 mg Lyophilized Powder for Injection (IV)USP Type I Amber Glass Vial with green flip-off seal Box of 1's | Rx | Sakar Healthcare Ltd.India | Central West Medicale Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6050-04 | Mar 25, 2030 | |
CirabRabeprazole sodium | 20 mg Lyophilized Powder for Injection (IV)10 mL USP Type I flint tubular glass vial with grey bromobutyl rubber plugs and flip off aluminum seal (Box of 1's) | Rx | Ciron Drugs & Pharmaceuticals Pvt. LimitedIndia | Biocare Lifesciences Inc, | DRP-7450 | Nov 6, 2027 | |
DoctraRabeprazole sodium | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Glorious Dexa Mandaya, Inc.Importer: Ambica International Corporation | DRP-4245-01 | Oct 12, 2028 | |
GerdsolRabeprazole sodium | 20 mg Enteric-coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | 228 Pharma TradingImporter: Ambica International Corporation | DRP-4245-02 | Oct 12, 2028 | |
GerdsolRabeprazole sodium | 20 mg Powder for Solution for Intravenous Injection10 mL-USP Type I Flint Glass vial + 5 mL Ampoule Water for Injection as Diluent (Box of 1's) | Rx | Sakar Healthcare Pvt. Ltd.India | 228 Pharma TradingImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-6763-01 | Jul 20, 2031 | |
ImrebRabeprazole Sodium | 20 mg Lyophilized Powder for Intravenous Injection10 mL Clear Colorless Glass Vial USP Type I Red Flip-Off Seal + 5 mL Ampoule of Water for Injection (as diluent) in a box Box of 1's | Rx | Gufic Biosciences Ltd.India | Philcare Pharma Inc.Importer: SRS Life Sciences Inc. | DRP-11230 | Oct 10, 2029 | |
Korab 20Rabeprazole sodium | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Kopran LimitedIndia | I.E. Medica, Inc. | DRP-9102 | Jan 12, 2031 | |
MaribezoleRabeprazole Sodium | 20 mg Enteric Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's). | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I - Solid Oral Dosage Facility)India | Ambica International Corporation.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-13554 | Mar 9, 2028 | |
NoneRabeprazole Sodium | 20 mg Enteric-Coated TabletAlu/PVC Blister Pack x 14's (Box of 28's) | Rx | Daewon Pharm. Co., Ltd.Republic of Korea | H & B Pharma International Inc. | DRP-6118 | Apr 27, 2031 | |
ParietRabeprazole Sodium | 10 mg TabletBlister Pack x 7's (Box of 14's) | Rx | Bushu Pharmaceuticals Ltd. (Misato Factory)Japan | Zuellig Pharma CorporationImporter: Hi-Esai Pharmaceutical, Inc. | DR-XY25304 | Jun 8, 2030 | |
ParietRabeprazole Sodium | 20 mg TabletBlister Pack x 7's (Box of 14's) | Rx | Bushu Pharmaceuticals Ltd. (Misato Factory)Japan | Zuellig Pharma CorporationImporter: HI-Eisai Pharmaceutical Inc. | DR-XY25303 | Jun 8, 2030 | |
PrasaveRabeprazole sodium | 20 mg Powder for Intravenous Injection10 mL USP Type III amber glass vial, grey bromo butyl rubber stopper, aluminum flip off seal and red plastic cap in clear PVC plastic tray (Box of 1's) | Rx | Indasi Lifescience Pvt. Ltd.India | Savelink Pharma And Trading Co.Importer: Aglobal Care Inc. | DRP-15090-01 | Apr 19, 2029 | |
Prasave-20Rabeprazole sodium | 20 mg Enteric-Coated TabletAlu / Alu Blister Pack x 10's (Box of 30's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Savelink Pharma and Trading Co.Importer: Aglobal Care, Inc. | DRP-13842-01 | Apr 28, 2028 | |
PrasberexRabeprazole Sodium | 20 mg Lyophilized Powder for Injection (IV)USP Type I Amber Glass Vial with green flip-off seal Box of 1's | Rx | Sakar Healthcare Pvt. Ltd.India | Pharma King DistributorImporter: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-6050-03 | Mar 25, 2030 | |
PrazoferRabeprazole Sodium | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Ravian Life Science Pvt. Ltd.India | Ferma Drug EnterprisesImporter: Pharmakon Biotec, Inc. | DRP-6028-04 | Feb 26, 2030 | |
PrazolifeRabeprazole Sodium | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10’s Box of 10’s | Rx | Akums Drugs & Pharmaceuticals, Inc.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Limited | DRP-6049-01 | Mar 25, 2030 | |
PromizoleRabeprazole Sodium | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Ravian Life Science Pvt. Ltd.India | Pro Medica Inc.Importer: Pharmakon Biotec Inc. | DRP-6028-03 | Feb 26, 2030 | |
Rabazio 20Rabeprazole sodium | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Agio Pharmaceuticals Ltd.India | Macropharma Corporation | DRP-15061 | Apr 1, 2029 | |
Rabb-20Rabeprazole sodium | 20 mg Lyophilized Powder for Injection (I.V.)10 mL-capacity USP Type I clear and colorless glass vial with grey butyl rubber stopper and aluminum seal. with red plastic flip-off cap (Box of 1's) | Rx | United Biotech Pvt. Ltd.India | Aglobal Care, Inc. | DRP-15201 | May 24, 2029 | |
Rabe-20Rabeprazole (as sodium) | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10's in Aluminum Pack (Box of 50's) | Rx | ARISTOPHARMA LTD.Bangladesh | Sahar International Trading Inc. | DRP-8559 | Dec 9, 2028 | |
RabecidRabeprazole Sodium | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | Rx | Ravian Life Science Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-6028 | Feb 26, 2030 | |
RabefazRabeprazole sodium | 20 mg Powder for Intravenous Injection.10 mL USP Type III amber glass vial, grey bromobutyl rubber stopper, aluminum flip of seal and red plastic cap in clear PVC plastic tray (Box of 1's) | Rx | Indasi Lifescience Pvt. Ltd.India | Aglobal Care, Inc. | DRP-15090 | Apr 19, 2029 | |
RabegastRabeprazole Sodium | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Ravian Life Science Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-6028-02 | Feb 26, 2030 | |
Rabeloc 20Rabeprazole (as Sodium) | 20 mg Enteric Coated TabletAlu-Alu Blister Pack x 10's (Monocarton of 10's, Box of 100's and Box of 50's) | Rx | Cadila Pharmaceuticals LimitedIndia | Biocare Lifesciences Inc. | DRP-3833 | Aug 13, 2031 | |
Rabeloc IVRabeprazole Sodium | 20 mg Powder for Solution for Injection (IV)USP Type I Flint Vial x 50 mL with full Slotted Grey Bromobutyl Rubber Stopper (Box of 1 's) | Rx | Cadila Pharmaceutical LimitedIndia | Biocare Lifesciences, Inc. | DRP-13707 | Nov 28, 2028 | |
RabemRabeprazole Sodium | 20mg Delayed Release TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-12164 | Jun 27, 2027 | |
RabenRabeprazole Sodium | 20 mg Lyophilized Powder for Injection (IV)USP Type I Amber Glass Vial with green flip-off seal (Box of 1's) | Rx | Sakar Healthcare Ltd.India | Tamiga Pharmaceuticals SupplyImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6050 | Mar 25, 2030 | |
RabepionRabeprazole Sodium | 20 mg Enteric Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s, 30's, 60's and 100's) | Rx | Lincoln Pharmaceuticals Ltd.India | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-11672-01 | Apr 11, 2027 | |
Rabesky-20Rabeprazole Sodium | 20mg Powder for Injection (I.V. Infusion)10 mL Type III Amber Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Red Flip- Off Seal Cap x 1's (Box of 1's) | Rx | Skymap Healthcare Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-14529 | Oct 2, 2028 | |
RabestaRabeprazole sodium | 20 mg Powder for Solution for Intravenous Injection10 mL USP Type I Flint Glass vial + 5 mL Ampoule Water for Injection as Diluent (Box of 1's) | Rx | Sakar Healthcare Ltd.India | 228 Pharma TradingImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-6763 | Jul 20, 2031 | |
Rabesta 10Rabeprazole Sodium | 10 mg Enteric-Coated TabletAlu/Alu Blister Pack x 15's Box of 30's | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-3092 | Jun 28, 2029 | |
Rabesta-20Rabeprazole sodium | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Macropharma CorporationImporter: Ambica International Corporation | DRP-4245 | Oct 12, 2028 | |
RabetorRabeprazole sodium | 20 mg Lyophilized Powder for Injection (I.V.)10 mL-capacity USP Type I clear and colorless glass vial with grey butyl rubber stopper and aluminum seal with red plastic flip-off cap (Box of 1's) | Rx | United Biotech Pvt. Ltd.India | Altor Pharmaceutical Product DistributionImporter: Triple Tact Import & Export Corp. | DRP-15201-01 | May 24, 2029 | |
RabezoRabeprazole sodium | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Aglobal Care, Inc. | DRP-13842 | Apr 28, 2028 | |
RabicorRabeprazole Sodium | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Checktrade Pharma Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-6049 | Mar 25, 2030 | |
RabprezRabeprazole sodium | 20 mg Powder for Solution for Intravenous Injection10 mL USP Type I Flint Glass vial + 5 mL Ampoule Water for Injection as Diluent (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Primeluck Trading CorporationImporter: Ambica International Corporation | DRP-6763-02 | Jul 20, 2031 | |
RabtamRabeprazole sodium | 20 mg Powder for Injection (IV Infusion)10 mL Type III Amber Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Red Flip-Off Seal Cap x 1’s (Box of 1’s and 10’s) | Rx | Skymap Pharmaceuticals Private LimitedIndia | Best ClearImporter: AMB HK Enterprises Inc. | DRP-14529-02 | Oct 2, 2028 | |
RaingraRabeprazole Sodium | 20 mg Enteric Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I - Solid Oral Dosage Facility)India | Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-13555 | Mar 9, 2028 | |
RapeedRabeprazole Sodium | 20 mg Lyophilized Powder for Injection (IV)USP Type I Amber Glass Vial with green flip-off seal (Box of 1's) | Rx | Sakar Healthcare Pvt. Ltd.India | Alkem Laboratories CorporationImporter: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-6050-01 | Mar 25, 2030 | |
ReloxaRabeprazole Sodium | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Ravian Life Science Pvt. Ltd.India | The Cathay Drug Co., Inc.Importer: Pharmakon Biotec Inc. | DRP-6028-01 | Feb 26, 2030 | |
ReloxaRabeprazole Sodium | 20 mg Lyophilized Powder for Intravenous Injection10 mL Clear Colorless Glass Vial USP Type I Red Flip-Off Seal + 5 mL Ampoule of Water for Injection (as diluent) in a box (Box of 1's) | Rx | Gufic Biosciences LimitedIndia | The Cathay Drug Co., Inc.Importer: SRS Life Sciences Inc. | DRP-11230-01 | Oct 10, 2029 | |
Repraz-20Rabeprazole | 20 mg Enteric-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Medley Pharmaceuticals LimitedIndia | Ambica International Corporation | DR-XY42011 | May 8, 2032 | |
RyanRabeprazole sodium | 20 mg Powder for Injection (IV Infusion)10 mL Type III Amber Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Red Flip-Off Seal Cap x 1’s (Box of 1’s and 10’s) | Rx | Skymap Pharmaceuticals Private LimitedIndia | Blue Medceuticals Marketing Corp.Importer: AMB HK Enterprises Inc. | DRP-14529-01 | Oct 2, 2028 | |
StrirabRabeprazole Sodium | 20 mg Sterile Lyophilized Powder for Injection (IV)10 mL USP Type I Flint Glass Vial stoppered with grey bromobutyl closure and flip-off aluminum seal (Box of 1's) | Rx | Gufic Biosciences LimitedIndia | Ambica International Corporation | DRP-8050 | Dec 18, 2028 | |
UnbrandedRabeprazole sodium | 10 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 14's (Box of 28's) | Rx | Daewon Pharm. Co., Ltd.Republic of Korea | H & B Pharma International Inc. | DR-XY45166 | Mar 3, 2031 | |
ZiomedrabRabeprazole Sodium | 20 mg Lyophilized Powder for Injection (IV)USP Type I Amber Glass Vial with Green Flip-Off Seal (Box of 1's) | Rx | Sakar Healthcare Pvt. Ltd.India | Zionmed Medical Supplies TradingImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-6050-02 | Mar 25, 2030 | |
(no brand name)Rabeprazole Sodium | 20 mg Enteric-Coated TabletAlu/Alu blister pack x 10's | Rx | Ind-Swift LimitedIndia | RiteMED Phils., Inc. | DR-XY41624 | Jan 28, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS ACIPHEX delayed-release tablets are provided in one strength, 20 mg. The tablets are round, light yellow, enteric coated, biconvex tablets. "ACIPHEX 20" is imprinted in red on one side of the tablet. Delayed-Release Tablets: 20 mg (3).
Warnings/Precautions
Gastric Malignancy: In adults, symptomatic response to therapy with rabeprazole does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing (5.1). Use with Warfarin: Monitor for increases in INR and prothrombin time (5.2, 7). Acute Tubulointerstitial Nephritis: Discontinue treatment and evaluate patients (5.3).
Clostridium difficile -Associated Diarrhea: PPI therapy may be associated with increased risk of (5.4). Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine (5.5). Severe Cutaneous Adverse Reactions: Discontinue at the first signs or symptoms of severe cutatneous adverse reactions or other signs of hypersensitivity and consider further evaluation (5.6).
Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous, new onset or exacerbation of existing disease; discontinue ACIPHEX and refer to specialist for evaluation (5.7). Cyanocobalamin (Vitamin B-12) Deficiency: Daily long-term use (e.g., longer than 3 years) may lead to malabsorption or a deficiency of cyanocobalamin (5.8).
Hypomagnesemia and Mineral Metabolism: Reported rarely with prolonged treatment with PPIs (5.9). Interaction with Methotrexate: Concomitant use with PPIs may elevate and/or prolong serum concentrations of …
5.1 Presence of Gastric Malignancy
5.1 Presence of Gastric Malignancy In adults, symptomatic response to therapy with ACIPHEX does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a PPI.
5.2 Interaction with Warfarin
5.2 Interaction with Warfarin Steady state interactions of rabeprazole and warfarin have not been adequately evaluated in patients. There have been reports of increased INR and prothrombin time in patients receiving a proton pump inhibitor and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death.
Patients treated with ACIPHEX delayed-release tablets and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time [see Drug Interactions (7)].
5.3 Acute Tubulointerstitial Nephritis
5.3 Acute Tubulointerstitial Nephritis Acute tubulointerstitial nephritis (TIN) has been observed in patients taking PPIs and may occur at any point during PPI therapy. Patients may present with varying signs and symptoms from symptomatic hypersensitivity reactions, to non-specific symptoms of decreased renal function (e.g., malaise, nausea, anorexia).
In reported case series, some patients were diagnosed on biopsy and in the absence of extra-renal manifestations (e.g., fever, rash or arthralgia). Discontinue ACIPHEX and evaluate patients with suspected acute TIN [see Contraindication (4)].
5.4 Clostridium difficile
5.4 Clostridium difficile -Associated Diarrhea Published observational studies suggest that PPI therapy like ACIPHEX may be associated with an increased risk of Clostridium difficile -associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve [see Adverse Reactions (6.2)].
Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Clostridium difficile- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents. For more information specific to antibacterial agents (clarithromycin and amoxicillin) indicated for use in combination with ACIPHEX, refer to Warnings and Precautions sections of the corresponding prescribing information.
5.5 Bone Fracture
5.5 Bone Fracture Several published observational studies in adults suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose, defined as multiple daily doses, and long-term PPI therapy (a year or longer).
Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to established treatment guidelines [see Dosage and Administration (2), Adverse Reactions (6.2)].
5.6 Severe Cutaneous Adverse Reactions
5.6 Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported in association with the use of PPIs [see Adverse Reactions (6.2)]. Discontinue ACIPHEX at first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation.
5.7 Cutaneous and Systemic Lupus Erythematosus
5.7 Cutaneous and Systemic Lupus Erythematosus Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs, including rabeprazole. These events have occurred as both new onset and an exacerbation of existing autoimmune disease. The majority of PPI-induced lupus erythematosus cases were CLE.
The most common form of CLE reported in patients treated with PPIs was subacute CLE (SCLE) and occurred within weeks to years after continuous drug therapy in patients ranging from infants to the elderly. Generally, histological findings were observed without organ involvement. Systemic lupus erythematosus (SLE) is less commonly reported than CLE in patients receiving PPIs.
PPI associated SLE is usually milder than non-drug induced SLE. Onset of SLE typically occurred within days to years after initiating treatment primarily in patients ranging from young adults to the elderly. The majority of patients presented with rash; however, arthralgia and cytopenia were also reported. Avoid administration of PPIs for longer than medically indicated.
If signs or symptoms consistent with CLE or SLE are noted in patients receiving ACIPHEX, discontinue the drug and refer the patient to the appropriate specialist for evaluation. Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks. Serological testing (e.g. ANA) may be positive and elevated serological test results may take longer to resolve than clinical manifestations.
5.8 Cyanocobalamin (Vitamin B-12) Deficiency
5.8 Cyanocobalamin (Vitamin B-12) Deficiency Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (vitamin B-12) caused by hypo- or achlorhydria. Rare reports of cyanocobalamin deficiency occurring with acid-suppressing therapy have been reported in the literature.
This diagnosis should be considered if clinical symptoms consistent with cyanocobalamin deficiency are observed in patients treated with ACIPHEX.
5.9 Hypomagnesemia and Mineral Metabolism
5.9 Hypomagnesemia and Mineral Metabolism Hypomagnesemia, symptomatic and asymptomatic, has been reported rarely in patients treated with PPIs for at least three months, in most cases after a year of therapy. Serious adverse events include tetany, arrhythmias, and seizures. Hypomagnesemia may lead to hypocalcemia and/or hypokalemia and may exacerbate underlying hypocalcemia in at-risk patients.
In most patients, treatment of hypomagnesemia required magnesium replacement and discontinuation of the PPI. For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2)].
Consider monitoring magnesium and calcium levels prior to initiation of ACIPHEX and periodically while on treatment in patients with a preexisting risk of hypocalcemia (e.g., hypoparathyroidism). Supplement with magnesium and/or calcium as necessary. If hypocalcemia is refractory to treatment, consider discontinuing the PPI.
5.10 Interaction with Methotrexate
5.10 Interaction with Methotrexate Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum concentrations of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients [see Drug Interactions (7)].
5.11 Fundic Gland Polyps
5.11 Fundic Gland Polyps PPI use is associated with an increased risk of fundic gland polyps that increases with long-term use, especially beyond one year. Most PPI users who developed fundic gland polyps were asymptomatic and fundic gland polyps were identified incidentally on endoscopy. Use the shortest duration of PPI therapy appropriate to the condition being treated.
Drug interactions
Drug interactions (US label) US FDA label
7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs.
Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets and Interactions with Diagnostics Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.
Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of drug resistance. Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with rabeprazole may increase toxicity.
There are other antiretroviral drugs which do not result in clinically relevant interactions with rabeprazole. Intervention: Rilpivirine-containing products: Concomitant use with ACIPHEX delayed-release tablets is contraindicated [see Contraindications (4)]. See prescribing information. Atazanavir: See prescribing information for atazanavir for dosing information.
Nelfinavir: Avoid concomitant use with ACIPHEX delayed-release tablets. See prescribing information for nelfinavir. Saquinavir: See the prescribing information for saquinavir and monitor for potential saquinavir toxicities. Other antiretrovirals: See prescribing information. Warfarin Clinical Impact: Increased INR and prothrombin time in patients receiving PPIs, including rabeprazole, and warfarin concomitantly.
Increases in INR and prothrombin time may lead to abnormal bleeding and even death [see Warnings and Precautions (5.2)]. Intervention: Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. Methotrexate Clinical Impact: Concomitant use of rabeprazole with methotrexate (primarily at high dose) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities.
No formal drug interaction studies of methotrexate with PPIs have been conducted [see Warnings and Precautions (5.9)]. Intervention: A temporary withdrawal of ACIPHEX delayed-release tablets may be considered in some patients receiving high dose methotrexate administration. Digoxin Clinical Impact: Potential for increased exposure of digoxin [see Clinical Pharmacology (12.3)].
Intervention: Monitor digoxin concentrations. Dose adjustment of digoxin may be needed to maintain therapeutic drug concentrations. See prescribing information for digoxin. Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.
Intervention: Mycophenolate mofetil (MMF): Co-administration of PPIs in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving ACIPHEX delayed-release tablets and MMF.
Use ACIPHEX delayed-release tablets with caution in transplant patients receiving MMF. See the prescribing information for other drugs dependent on gastric pH for absorption. Combination Therapy with Clarithromycin and Amoxicillin Clinical Impact: Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions, including potentially fatal arrhythmias, and are contraindicated.
Amoxicillin also has drug interactions. Intervention: See Contraindications and Warnings and Precautions in prescribing information for clarithromycin. See Drug Interactions in prescribing information for amoxicillin. Tacrolimus Clinical Impact: Potentially increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.
Intervention: Monitor tacrolimus whole blood trough concentrations. Dose adjustment of tacrolimus may be needed to maintain therapeutic drug concentrations. See prescribing information for tacrolimus. Interactions with Investigations of Neuroendocrine Tumors Clinical Impact: Serum chromogranin A (CgA) levels increase secondary to PPI-induced decreases in gastric acidity.
The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Intervention: Temporarily stop ACIPHEX delayed-release tablets treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g. for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary.
Interaction with Secretin Stimulation Test Clinical Impact: Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma. Intervention: Temporarily stop treatment with ACIPHEX delayed-release tablets at least 14 days before assessing to allow gastrin levels to return to baseline.
False Positive Urine Tests for THC Clinical Impact: There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs. Intervention: An alternative confirmatory method should be considered to verify positive results. See full prescribing information for a list of clinically important drug interactions (7).
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
In vitro studies have demonstrated that rabeprazole is metabolized in the liver primarily by cytochromes P450 3A (CYP3A) to a sulphone metabolite and cytochrome P450 2C19 (CYP2C19) to desmethyl rabeprazole.
CYP2C19 exhibits a known genetic polymorphism due to its deficiency in some sub-populations (e.g., 3 to 5% of Caucasians and 17 to 20% of Asians).
Drug Interaction Studies Combined Administration with Antimicrobials: Sixteen healthy subjects genotyped as extensive metabolizers with respect to CYP2C19 were given 20 mg ACIPHEX delayed-release tablets, 1000 mg amoxicillin, 500 mg clarithromycin, or all 3 drugs in a four-way crossover study.
Effects of Rabeprazole on Other Drugs Studies in healthy subjects have shown that rabeprazole does not have clinically significant interactions with other drugs metabolized by the CYP450 system, such as theophylline (CYP1A2) given as single oral doses, diazepam (CYP2C9 and CYP3A4) as a single intravenous dose, and phenytoin (CYP2C9 and CYP2C19) given as a single intravenous dose (with supplemental oral dosing).
Clopidogrel: Clopidogrel is metabolized to its active metabolite in part by CYP2C19.
A study of healthy subjects including CYP2C19 extensive and intermediate metabolizers receiving once daily administration of clopidogrel 75 mg concomitantly with placebo or with 20 mg ACIPHEX delayed-release tablets (n=36), for 7 days was conducted.
Tacrolimus Clinical Impact: Potentially increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19 .
Adverse reactions
The following serious adverse reactions are described below and elsewhere in labeling: Acute Tubulointerstitial Nephritis [see Warnings and Precautions (5.3)] Clostridium difficile- Associated Diarrhea [see Warnings and Precautions (5.4)] Bone Fracture [see Warnings and Precautions (5.5)] Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions (5.7)] Cyanocobalamin (Vitamin B-12) Deficiency [see Warnings and Precautions (5.8)] Hypomagnesemia and Mineral Metabolism [see Warnings and Precautions (5.9)] Fundic Gland Polyps [see Warnings and Precautions (5.11)] Most common adverse reactions in adults (>2%) are pain, pharyngitis, flatulence, infection, and constipation (6.1). Most common adverse reactions in adolescents (≥2%) are headache, diarrhea, nausea, vomiting, and abdominal pain (6.1).
To report SUSPECTED ADVERSE REACTIONS, contact Waylis Therapeutics LLC at 1-844-944-0912 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
6.1 Clinical Studies Experience
6.1 Clinical Studies Experience Because clinical trials are conducted under varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adults The data described below reflect exposure to ACIPHEX delayed-release tablets in 1064 adult patients exposed for up to 8 weeks.
The studies were primarily placebo- and active-controlled trials in adult patients with Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD), Duodenal Ulcers and Gastric Ulcers. The population had a mean age of 53 years (range 18-89 years) and had a ratio of approximately 60% male: 40% female. The racial distribution was 86% Caucasian, 8% African American, 2% Asian, and 5% other.
Most patients received either 10 mg, 20 mg or 40 mg per day of ACIPHEX delayed-release tablets. An analysis of adverse reactions appearing in ≥2% of patients treated with ACIPHEX delayed-release tablets (n=1064) and with a greater frequency than placebo (n=89) in controlled North American and European acute treatment trials, revealed the following adverse reactions: pain (3% vs. 1%), pharyngitis (3% vs. 2%), flatulence (3% vs. 1%), infection (2% vs. 1%), and constipation (2% vs. 1%).
Three long-term maintenance studies consisted of a total of 740 adult patients; at least 54% of adult patients were exposed to ACIPHEX delayed-release tablets for 6 months and at least 33% were exposed for 12 months. Of the 740 adult patients, 247 (33%) and 241 (33%) patients received 10 mg and 20 mg of ACIPHEX delayed-release tablets, respectively, while 169 (23%) patients received placebo and 83 (11%) received omeprazole.
The safety profile of rabeprazole in the maintenance studies in adults was consistent with what was observed in the acute studies. Less common adverse reactions seen in controlled clinical trials (<2% of patients treated with ACIPHEX delayed-release tablets and greater than placebo) and for which there is a possibility of a causal relationship to rabeprazole, include the following: headache, abdominal pain, diarrhea, dry mouth, dizziness, peripheral edema, hepatic enzyme increase, hepatitis, hepatic encephalopathy, myalgia, and arthralgia.
Combination Treatment with Amoxicillin and Clarithromycin: In clinical trials using combination therapy with rabeprazole plus amoxicillin and clarithromycin (RAC), no adverse reactions unique to this drug combination were observed. In the U.S. multicenter study, the most frequently reported drug related adverse reactions for patients who received RAC therapy for 7 or 10 days were diarrhea (8% and 7%) and taste perversion (6% and 10%), respectively.
No clinically significant laboratory abnormalities particular to the drug combinations were observed. For more information on adverse reactions or laboratory changes with amoxicillin or clarithromycin, refer to their respective prescribing information, Adverse Reactions section. Pediatrics In a multicenter, open-label study of adolescent patients 12 to 16 years of age with a clinical diagnosis of symptomatic GERD or endoscopically proven GERD, the adverse event profile was similar to that of adults.
The adverse reactions reported without regard to relationship to ACIPHEX delayed-release tablets that occurred in ≥2% of 111 patients were headache (9.9%), diarrhea (4.5%), nausea (4.5%), vomiting (3.6%), and abdominal pain (3.6%). The related reported adverse reactions that occurred in ≥2% of patients were headache (5.4%) and nausea (1.8%).
There were no adverse reactions reported in this study that were not previously observed in adults.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of rabeprazole. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Blood and Lymphatic System Disorders: agranulocytosis, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia Ear and Labyrinth Disorders: vertigo Eye Disorders: blurred vision Gastrointestinal Disorders: fundic gland polyps General Disorders and Administration Site Conditions: sudden death Hepatobiliary Disorders: jaundice Immune System Disorders: anaphylaxis, angioedema, systemic lupus erythematosus, Stevens-Johnson syndrome, toxic epidermal necrolysis (some fatal), DRESS, AGEP Infections and Infestations: Clostridium difficile -associated diarrhea Investigations: Increases in prothrombin time/INR (in patients treated with concomitant warfarin), TSH elevations Metabolism and Nutrition Disorders: hyperammonemia, hypomagnesemia, hypocalcemia, hypokalemia [Warnings and Precautions 5.8], hyponatremia Musculoskeletal System Disorders: bone fracture, rhabdomyolysis Nervous System Disorders: coma Psychiatric Disorders: delirium, disorientation Renal and Genitourinary Disorders: interstitial nephritis, erectile dysfunction Respiratory, Thoracic and Mediastinal Disorders: interstitial pneumonia Skin and Subcutaneous Tissue Disorders: severe dermatologic reactions including bullous and other drug eruptions of the skin, cutaneous lupus erythematosus, erythema multiforme
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary There are no available human data on ACIPHEX use in pregnant women to inform the drug associated risk. The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies.
No evidence of adverse developmental effects were seen in animal reproduction studies with rabeprazole administered during organogenesis at 13 and 8 times the human area under the plasma concentration-time curve (AUC) at the recommended dose for GERD, in rats and rabbits, respectively [see Data]. Changes in bone morphology were observed in offspring of rats treated with oral doses of a different PPI through most of pregnancy and lactation.
When maternal administration was confined to gestation only, there were no effects on bone physeal morphology in the offspring at any age [see Data]. Data Animal Data Embryo-fetal developmental studies have been performed in rats during organogenesis at intravenous doses of rabeprazole up to 50 mg/kg/day (plasma AUC of 11.8 µg∙hr/mL, about 13 times the human exposure at the recommended oral dose for GERD) and rabbits at intravenous doses up to 30 mg/kg/day (plasma AUC of 7.3 µg∙hr/mL, about 8 times the human exposure at the recommended oral dose for GERD) and have revealed no evidence of harm to the fetus due to rabeprazole.
Administration of rabeprazole to rats in late gestation and during lactation at an oral dose of 400 mg/kg/day (about 195-times the human oral dose based on mg/m 2) resulted in decreases in body weight gain of the pups. A pre- and postnatal developmental toxicity study in rats with additional endpoints to evaluate bone development was performed with a different PPI at about 3.4 to 57 times an oral human dose on a body surface area basis.
Decreased femur length, width and thickness of cortical bone, decreased thickness of the tibial growth plate, and minimal to mild bone marrow hypocellularity were noted at doses of this PPI equal to or greater than 3.4 times an oral human dose on a body surface area basis. Physeal dysplasia in the femur was also observed in offspring after in utero and lactational exposure to the PPI at doses equal to or greater than 33.6 times an oral human dose on a body surface area basis.
Effects on maternal bone were observed in pregnant and lactating rats in a pre- and postnatal toxicity study when the PPI was administered at oral doses of 3.4 to 57 times an oral human dose on a body surface area basis. When rats were dosed from gestational day 7 through weaning on postnatal day 21, a statistically significant decrease in maternal femur weight of up to 14% (as compared to placebo treatment) was observed at doses equal to or greater than 33.6 times an oral human dose on a body surface area basis.
A follow-up developmental toxicity study in rats with further time points to evaluate pup bone development from postnatal day 2 to adulthood was performed with a different PPI at oral doses of 280 mg/kg/day (about 68 times an oral human dose on a body surface area basis) where drug administration was from either gestational day 7 or gestational day 16 until parturition. When maternal administration was confined to gestation only, there were no effects on bone physeal morphology in the offspring at any age.
Mechanism of action
12.1 Mechanism of Action Rabeprazole belongs to a class of antisecretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H 2 -receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H +, K + ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor.
Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds. It inhibits acid transport in porcine gastric vesicles with a half-life of 90 seconds.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Antisecretory Activity The antisecretory effect begins within one hour after oral administration of 20 mg ACIPHEX delayed-release tablets. The median inhibitory effect of rabeprazole on 24 hour gastric acidity is 88% of maximal after the first dose. A 20 mg dose of ACIPHEX delayed-release tablets inhibits basal and peptone meal-stimulated acid secretion versus placebo by 86% and 95%, respectively, and increases the percent of a 24-hour period that the gastric pH>3 from 10% to 65% (see table below).
This relatively prolonged pharmacodynamic action compared to the short pharmacokinetic half-life (1 to 2 hours) reflects the sustained inactivation of the H +, K + ATPase. Table 3: Gastric Acid Parameters: ACIPHEX Delayed-Release Tablets versus Placebo After 7 Days of Once Daily Dosing Parameter ACIPHEX delayed-release tablets (20 mg once daily) Placebo Basal Acid Output (mmol/hr) 0.4 (p<0.01 versus placebo) 2.8 Stimulated Acid Output (mmol/hr) 0.6 13.3 % Time Gastric pH>3 65 10 Compared to placebo, 10 mg, 20 mg, and 40 mg of ACIPHEX delayed-release tablets, administered once daily for 7 days significantly decreased intragastric acidity with all doses for each of four meal-related intervals and the 24-hour time period overall.
In this study, there were no statistically significant differences between doses; however, there was a significant dose-related decrease in intragastric acidity. The ability of rabeprazole to cause a dose-related decrease in mean intragastric acidity is illustrated below. Table 4: AUC Acidity (Mmol ∙ Hr/L): ACIPHEX Delayed-Release Tablets versus Placebo on Day 7 of Once Daily Dosing (Mean±SD) ACIPHEX delayed-release tablets Placebo (N=24) AUC interval (hrs) 10 mg (N=24) 20 mg (N=24) 40 mg (N=24) 08:00 – 13:00 19.6±21.5 (p<0.001 versus placebo) 12.9±23 7.6±14.7 91.1±39.7 13:00 – 19:00 5.6±9.7 8.3±29.8 1.3±5.2 95.5±48.7 19:00 – 22:00 0.1±0.1 0.1±0.06 0.0±0.02 11.9±12.5 22:00 – 08:00 129.2±84 109.6±67.2 76.9±58.4 479.9±165 AUC 0-24 hours 155.5±90.6 130.9±81 85.8±64.3 678.5±216 After administration of 20 mg ACIPHEX delayed-release tablets once daily for eight days, the mean percent of time that gastric pH greater than 3 or gastric pH greater than 4 after a single dose (Day 1) and multiple doses (Day 8) was significantly greater than placebo (see table below).
The decrease in gastric acidity and the increase in gastric pH observed with 20 mg ACIPHEX delayed-release tablets administered once daily for eight days were compared to the same parameters for placebo, as illustrated below: Table 5: Gastric Acid Parameters ACIPHEX Delayed-Release Tablets Once Daily Dosing versus Placebo on Day 1 and Day 8 ACIPHEX delayed-release tablets 20 mg once daily Placebo Parameter Day 1 Day 8 Day 1 Day 8 Mean AUC 0-24 Acidity 340.8 (p<0.001 versus placebo) 176.9 925.5 862.4 Median trough pH (23-hr) No inferential statistics conducted for this parameter. 3.77 3.51 1.27 1.38 % Time Gastric pH greater than 3 Gastric pH was measured every hour over a 24-hour period. 54.6 68.7 19.1 21.7 % Time Gastric pH greater than 4 44.1 60.3 7.6 11.0 Effects on Esophageal Acid Exposure In patients with GERD and moderate to severe esophageal acid exposure, a dose of 20 mg and 40 mg per day of ACIPHEX delayed-release tablets decreased 24-hour esophageal acid exposure. After seven days of treatment, the percentage of time that the esophageal pH was less than 4 decreased from baselines of 24.7% for 20 mg and 23.7% for 40 mg, to 5.1% and 2.0%, respectively.
Normalization of 24-hour intraesophageal acid exposure was correlated to gastric pH greater than 4 for at least 35% of the 24-hour period; this level was achieved in 90% of subjects receiving ACIPHEX 20 mg and in 100% of subjects receiving ACIPHEX 40 mg. With ACIPHEX 20 mg and 40 mg per day, significant effects on gastric and esophageal pH were noted after one day of treatment, and more pronounced after seven days of treatment.
Effects on Serum Gastrin The median fasting gastrin level increased in a dose-related manner in patients treated once daily with ACIPHEX delayed-release tablets for up to eight weeks for ulcerative or erosive esophagitis and in patients treated for up to 52 weeks to prevent recurrence of disease. The group median values stayed within the normal range.
In a group of subjects treated with 20 mg ACIPHEX delayed-release tablets for 4 weeks a doubling of mean serum gastrin concentrations was observed. Approximately 35% of these treated subjects developed serum gastrin concentrations above the upper limit of normal. Effects on Enterochromaffin-like (ECL) Cells Increased serum gastrin secondary to antisecretory agents stimulates proliferation of gastric ECL cells which, over time, may result in ECL cell hyperplasia in rats and mice and gastric carcinoids in rats, especially in females [see Nonclinical Toxicology (13.1)].
In over 400 patients treated with ACIPHEX delayed-release tablets (10 or 20 mg) once daily for up to one year, the incidence of ECL cell hyperplasia increased with time and dose, which is consistent with the pharmacological action of the proton pump inhibitor. No patient developed the adenomatoid, dysplastic or neoplastic changes of ECL cells in the gastric mucosa.
No patient developed the carcinoid tumors observed in rats. Endocrine Effects Studies in humans for up to one year have not revealed clinically significant effects on the endocrine system. In healthy male subjects treated with ACIPHEX delayed-release tablets for 13 days, no clinically relevant changes have been detected in the following endocrine parameters examined: 17 β-estradiol, thyroid stimulating hormone, tri-iodothyronine, thyroxine, thyroxine-binding protein, parathyroid hormone, insulin, glucagon, renin, aldosterone, follicle-stimulating hormone, luteotrophic hormone, prolactin, somatotrophic hormone, dehydroepiandrosterone, cortisol-binding globulin, and urinary 6β-hydroxycortisol, serum testosterone and circadian cortisol profile.
Other Effects In humans treated with ACIPHEX delayed-release tablets for up to one year, no systemic effects have been observed on the central nervous, lymphoid, hematopoietic, renal, hepatic, cardiovascular, or respiratory systems. No data are available on long-term treatment with ACIPHEX delayed-release tablets and ocular effects.
Pharmacokinetics
Excretion: Following a single 20 mg oral dose of 14 C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; its glucuronide, and mercapturic acid metabolites.
Patients with Hepatic Impairment: In a single dose study of 10 patients with mild to moderate hepatic impairment (Child-Pugh Class A and B, respectively) who were administered a single 20 mg dose of ACIPHEX delayed-release tablets, AUC 0-24 was approximately doubled, the elimination half-life was 2- to 3-fold higher, and total body clearance was decreased to less than half compared to values in healthy men.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics After oral administration of 20 mg ACIPHEX delayed-release tablets, peak plasma concentrations (C max) of rabeprazole occur over a range of 2 to 5 hours (T max). The rabeprazole C max and AUC are linear over an oral dose range of 10 mg to 40 mg. There is no appreciable accumulation when doses of 10 mg to 40 mg are administered every 24 hours; the pharmacokinetics of rabeprazole is not altered by multiple dosing.
Absorption Absolute bioavailability for a 20 mg oral tablet of rabeprazole (compared to intravenous administration) is approximately 52%. When ACIPHEX delayed-release tablets are administered with a high fat meal, T max is variable; which concomitant food intake may delay the absorption up to 4 hours or longer. However, the C max and the extent of rabeprazole absorption (AUC) are not significantly altered.
Thus ACIPHEX delayed-release tablets may be taken without regard to timing of meals. Distribution Rabeprazole is 96.3% bound to human plasma proteins. Elimination Metabolism: Rabeprazole is extensively metabolized. A significant portion of rabeprazole is metabolized via systemic nonenzymatic reduction to a thioether compound.
Rabeprazole is also metabolized to sulphone and desmethyl compounds via cytochrome P450 in the liver. The thioether and sulphone are the primary metabolites measured in human plasma. These metabolites were not observed to have significant antisecretory activity. In vitro studies have demonstrated that rabeprazole is metabolized in the liver primarily by cytochromes P450 3A (CYP3A) to a sulphone metabolite and cytochrome P450 2C19 (CYP2C19) to desmethyl rabeprazole.
CYP2C19 exhibits a known genetic polymorphism due to its deficiency in some sub-populations (e.g., 3 to 5% of Caucasians and 17 to 20% of Asians). Rabeprazole metabolism is slow in these sub-populations, therefore, they are referred to as poor metabolizers of the drug. Excretion: Following a single 20 mg oral dose of 14 C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; its glucuronide, and mercapturic acid metabolites.
The remainder of the dose was recovered in the feces. Total recovery of radioactivity was 99.8%. No unchanged rabeprazole was recovered in the urine or feces. Specific Populations Geriatric Patients: In 20 healthy elderly subjects administered 20 mg ACIPHEX delayed-release tablets once daily for seven days, AUC values approximately doubled and the C max increased by 60% compared to values in a parallel younger control group.
There was no evidence of drug accumulation after once daily administration [see Use in Specific Population (8.5)]. Pediatric Patients: The pharmacokinetics of rabeprazole was studied in 12 adolescent patients with GERD 12 to 16 years of age, in a multicenter study. Patients received 20 mg ACIPHEX delayed-release tablets once daily for five or seven days.
An approximate 40% increase in rabeprazole exposure was noted following 5 to 7 days of dosing compared with the exposure after 1 day dosing. Pharmacokinetic parameters in adolescent patients with GERD 12 to 16 years of age were within the range observed in healthy adult subjects. Male and Female Patients and Racial or Ethnic Groups: In analyses adjusted for body mass and height, rabeprazole pharmacokinetics showed no clinically significant differences between male and female subjects.
In studies that used different formulations of rabeprazole, AUC 0-∞ values for healthy Japanese men were approximately 50 to 60% greater than values derived from pooled data from healthy men in the United States. Patients with Renal Impairment: In 10 patients with stable end-stage renal disease requiring maintenance hemodialysis (creatinine clearance ≤5 mL/min/1.73 m²), no clinically significant differences were observed in the pharmacokinetics of rabeprazole after a single 20 mg dose of ACIPHEX delayed-release tablets when compared to 10 healthy subjects.
Patients with Hepatic Impairment: In a single dose study of 10 patients with mild to moderate hepatic impairment (Child-Pugh Class A and B, respectively) who were administered a single 20 mg dose of ACIPHEX delayed-release tablets, AUC 0-24 was approximately doubled, the elimination half-life was 2- to 3-fold higher, and total body clearance was decreased to less than half compared to values in healthy men. In a multiple dose study of 12 patients with mild to moderate hepatic impairment administered 20 mg ACIPHEX delayed-release tablets once daily for eight days, AUC 0-∞ and C max values increased approximately 20% compared to values in healthy age- and gender-matched subjects.
These increases were not statistically significant. No information exists on rabeprazole disposition in patients with severe hepatic impairment (Child-Pugh Class C) [see Use in Specific Populations (8.6)]. Drug Interaction Studies Combined Administration with Antimicrobials: Sixteen healthy subjects genotyped as extensive metabolizers with respect to CYP2C19 were given 20 mg ACIPHEX delayed-release tablets, 1000 mg amoxicillin, 500 mg clarithromycin, or all 3 drugs in a four-way crossover study.
Each of the four regimens was administered twice daily for 6 days. The AUC and C max for clarithromycin and amoxicillin were not different following combined administration compared to values following single administration. However, the rabeprazole AUC and C max increased by 11% and 34%, respectively, following combined administration.
The AUC and C max for 14-hydroxyclarithromycin (active metabolite of clarithromycin) also increased by 42% and 46%, respectively. This increase in exposure to rabeprazole and 14-hydroxyclarithromycin is not expected to produce safety concerns. Effects of Other Drugs on Rabeprazole Antacids: Co-administration of ACIPHEX delayed-release tablets and antacids produced no clinically relevant changes in plasma rabeprazole concentrations.
Effects of Rabeprazole on Other Drugs Studies in healthy subjects have shown that rabeprazole does not have clinically significant interactions with other drugs metabolized by the CYP450 system, such as theophylline (CYP1A2) given as single oral doses, diazepam (CYP2C9 and CYP3A4) as a single intravenous dose, and phenytoin (CYP2C9 and CYP2C19) given as a single intravenous dose (with supplemental oral dosing). Steady state interactions of rabeprazole and other drugs metabolized by this enzyme system have not been studied in patients.
Clopidogrel: Clopidogrel is metabolized to its active metabolite in part by CYP2C19. A study of healthy subjects including CYP2C19 extensive and intermediate metabolizers receiving once daily administration of clopidogrel 75 mg concomitantly with placebo or with 20 mg ACIPHEX delayed-release tablets (n=36), for 7 days was conducted.
The mean AUC of the active metabolite of clopidogrel was reduced by approximately 12% (mean AUC ratio was 88%, with 90% CI of 81.7 to 95.5%) when ACIPHEX delayed-release tablets were coadministered compared to administration of clopidogrel with placebo [see Drug Interactions (7)]. Digoxin: In healthy adult subjects (n=16), co-administration of 20 mg rabeprazole sodium delayed-release tablets with 2.5 mg once daily doses of digoxin at steady state resulted in approximately 29% and 19% increase in mean C max and AUC (0-24) of digoxin [see Drug Interactions (7)].
Ketoconazole: In healthy adult subjects (n=19), co-administration of 20 mg rabeprazole sodium delayed-release tablets at steady state with a single 400 mg oral dose ketoconazole resulted in approximately an average of 31% reduction in both C max and AUC (0-inf) of ketoconazole [see Drug Interactions (7)]. Cyclosporine:In vitro incubations employing human liver microsomes indicated that rabeprazole inhibited cyclosporine metabolism with an IC 50 of 62 micromolar, a concentration that is over 50 times higher than the C max in healthy volunteers following 14 days of dosing with 20 mg of ACIPHEX delayed-release tablets.
This degree of inhibition is similar to that by omeprazole at equivalent concentrations.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Rabeprazole (as Sodium) 20 mg Tablet | ₱6.12–₱15.00Reference ₱13.00 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Rabeprazole sodium |
| PNF listing | Oral: 10 mg and 20 mg tablets |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Aciphex · Waylis Therapeutics LLC [US FDA-approved label, version 3, January 27, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1eb38279-0237-4967-be7a-c53a826c1138
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .